Celgene Passes on Option-to-Buy $600 Million Deal for Boston's Acetylon
Xconomy Boston — The option-to-buy deal, in biotech, is a way to hedge a bet. A big firm will pay a fee for the right to acquire a smaller company later on, with the big bucks coming only if the acquisition is triggered.
An option isn’t a guarantee, however; a big company can always pass on a buyout, leaving the smaller biotech to chart a new course. This has happened a handful of times over the past few years, and a partnership between Celgene and Acetylon Pharmaceuticals has become the latest example.
An option isn’t a guarantee, however; a big company can always pass on a buyout, leaving the smaller biotech to chart a new course. This has happened a handful of times over the past few years, and a partnership between Celgene and Acetylon Pharmaceuticals has become the latest example.